Transferability of dermal temperature histamine sensitization test for estimation of pertussis toxin activity in vaccines

Human Vaccines

Volumn 5, Issue 3, 2009, Pages 166-171

  Gaines Das, Rose ^a   Ochiai, Masaki ^b   Douglas Bardsley, Alex ^a   Asokanathan, Cathy ^a   Horiuchi, Yoshi ^b   Rigsby, Peter ^a   Corbel, Michael J ^a   Xing, Dorothy K L ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Acellular pertussis vaccine; Histamine sensitisation test; Pertussis toxin

Indexed keywords

PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXPERIMENTAL MOUSE; FEMALE; HISTAMINE RELEASE; HISTAMINE SENSITIVITY; LETHALITY; MOUSE; NONHUMAN; REPRODUCIBILITY; SKIN SENSITIZATION; SKIN TEMPERATURE; TEMPERATURE MEASUREMENT; TOXICITY TESTING; TOXIN ANALYSIS; VACCINATION;

ANIMALS; FEMALE; HUMANS; JAPAN; MICE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; QUALITY CONTROL; SKIN TEMPERATURE; TOXICITY TESTS;

EID: 67549140834     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.3.6615     Document Type: Article

References (34)

1. WHO position paper Weekly Epidemiological Record 2005; 80:29-40. Also available at www.who.int/wer/2005/wer8004.pdf.
2. Munoz JJ. Biological activities of pertussigen (pertussis toxin) In: Sekura RD, Moss J, Vaughan M, ed. Pertussis toxin, Academic press inc., London 1985; 1-18.
3. Miller D, Madge N, Diamond J, Wadsworth J, Ross E. Pertussis immunization and serious acute neurological illnesses in children. Br Med J 1993; 307:1171-76.
4. Donnelly S, Loscher CE, Lynch MA, Mills KHG. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1β in a new murine model for analysis of neuronal side effects of vaccination. Infect Immun 2001; 69:4217-23.
5. Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth-dose of acellular pertussis vaccine in south Australia. Med J Aust 2003; 179:191-4.
6. Skowronski DM, Remple VP, Macnabb J, Pielak K, Patrick DM, Halperin SA, Scheifele D. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics 2003; 112:453.
7. Yamamoto A, Nagata N, Ochiai M, Kataoka M, Toyoizumi H, Okada K, et al. Enhanced sensitization of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunization. Vaccine 2002; 20:3088-94.
8. Locht C, Antoine R. Bordetella pertussis protein toxins. In: Alouf JE, Freer JH eds. Bacterial protein toxins. Second edition, Academic press, London 1999; 130-46.
9. Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996; 14:359-68.
10. Diphtheria-pertussis-tetanus combination vaccine, In: Minimum requirements for Biological products. Association of Biologicals Manufacturers of Japan 1986; 41-9.
11. Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. In: WHO Technical Report Series No. 878; 1998; 57-72.
12. Title 21, Pertussis vaccine 620.1. In: U.S. Code of Federal Regulations. Washington DC, U.S. Government Printing Office 1983; 58-61.
13. Pertussis vaccine (acellular, component, adsorbed), In: European Pharmacopoeia-Supplement 2000; 1050-2.
14. Kappelle IS, Gun JW, Marsman FR, Hendriksen C, Donk H. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. Biologicals 1997; 25:41-57.
15. Corbel MJ, Xing DK. Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vaccines 2004; 3:89-101.
16. Ishida S, Kurokawa M, Asakawa S, Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. J Biol Stand 1979; 7:21-9.
17. Diphtheria-pertussis-tetanus combination vaccine, In: Minimum requirements for Biological products. Ministry of Health, Labour and Welfare, Japanese Government 2004.
18. Ochiai M, Yamamoto A, Kataoka M, Toyoizumi H, Arakawa Y, Horiuchi Y. Highly sensitive histamine-sensitization test for residual activity of pertussis toxin in acellular pertussis vaccine, Biologicals 2007; 35:259-64
19. Gaines Das RE, North D. Implications of experimental technique for analysis and interpretation of data from animal experiments: outliers and increased varaiblity resulting from failure of intraperitoneal injection procedures. Lab Anim 2007; 41:312-20.
20. Claassen V. Intraperitoneal drug administration. Neglected Factors in Pharmacology and Neuroscience Research. In: Huston JP, ed. Techniques in the Behavioral and Neural Sciences vol. 12. Amsterdam: Elsevier 1994.
21. Svendsen O. Letter to the editor: Ethics and animal welfare related to in vivo pharmacology and toxicology in laboratory animals, Basic Clin Pharmacol and Toxicol 2005; 97:197-9.
22. Manclark CR, Hansen CT, Treadwell PE, Pittman M. Selective breeding to establish a standard mouse for pertussis vaccine bioassay II. Bioresponses of mice susceptible and resistant to sensitization by pertussis vaccine HSF. J Biol Stand 1975; 3:353-63.
23. Munoz JJ, Bergman RK. Bordetella pertussis: immunological and other biological activities. In: Immunology, vol. 4. New York and Basel: Marcel Dekker Inc 1977.
24. Xing D, Das RG, Newland P, Corbel M. Comparison of the bioactivity of reference preparations for assaying Bordetella pertussis toxin activity in vaccines by the histamine sensitization and Chinese hamster ovary-cell tests: assessment of validity of expression of activity in terms of protein concentration. Vaccine 2002; 20:3535-42.
25. Miles AA. Biological standards and the measurement of therapeutic activity. Bri Med Bull 1951; 7:283-91.
26. Brennan MJ, David JL, Kenimer JG, Manclark CR. Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein. J Biol Chem 1988; 263:4895-9.
27. Burns DL, Kenimer JG, Manclark CR. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun 1987; 55:24-8.
28. Cyr T, Menzies AJ, Calver J, Whitehouse LW. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products. Biologicals 2001; 29:81-95.
29. Yuen CT, Canthaboo C, Menzies JA, Cyr LW, Whitehouse KW, Corbel MJ, et al. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay. Vaccine 2002; 21:44-52.
30. Gomez SR, Yuen CT, Asokanathan C, Douglas-Bardsley A, Corbel MJ, Coote JG, et al. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitization test. Vaccine 2007; 25:3311-18.
31. Gomez SR, Xing D, Corbel MJ, Rigsby P, Parton R, Coote JG, et al. Development of a carbohydrate binding assay for the determination of B-subunit activity in pertussis toxin or toxoid. Anal Biochem 2006; 356:244-53.
32. Xing DKL, Corbel MJ, Dobbelaer R, Knezevic I. WHO Working Group on standardization and control of acellular pertussis vaccines- report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom, Vaccine 2007; 25:2749-57.
33. Knezevic I, Baca-Estrada M, Xing DK, Lei D, on behalf of the WHO Working Group on Acellular Pertussis Vaccines. WHO Working Group meeting on Standardization of Acellular Pertussis Vaccines: potency assay. 7-9 November 2007, Beijing, China. Vaccine 2008 (in press).
34. Gaines Das RE, Rice LR. SCAN, an exploratory program for preliminary analysis of bioassay and immunoassay data. Comput Methods Programs Biomed 1985; 21:25-33.